Medifast Inc (NYSE:MED) has been given an average recommendation of “Hold” by the six brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $112.50.

MED has been the topic of several analyst reports. B. Riley initiated coverage on shares of Medifast in a research report on Thursday, June 25th. They set a “buy” rating and a $164.00 price target on the stock. DA Davidson boosted their price target on shares of Medifast from $83.00 to $86.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Finally, Zacks Investment Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating and set a $110.00 target price on the stock in a report on Tuesday, May 12th.

MED traded up $2.17 during trading on Thursday, reaching $138.77. 15,089 shares of the company’s stock were exchanged, compared to its average volume of 239,863. The company’s fifty day moving average price is $105.45 and its 200-day moving average price is $92.19. Medifast has a fifty-two week low of $49.03 and a fifty-two week high of $136.79. The firm has a market capitalization of $1.61 billion, a PE ratio of 22.06 and a beta of 1.23.

Medifast (NYSE:MED) last announced its quarterly earnings results on Tuesday, May 5th. The specialty retailer reported $1.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.60. The company had revenue of $178.46 million during the quarter, compared to analyst estimates of $161.90 million. Medifast had a net margin of 10.41% and a return on equity of 65.66%. Equities research analysts forecast that Medifast will post 7.27 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 6th. Investors of record on Tuesday, June 30th will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 3.26%. The ex-dividend date is Monday, June 29th. Medifast’s payout ratio is 75.84%.

In other news, Director Scott Schlackman sold 3,119 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $107.55, for a total transaction of $335,448.45. Following the completion of the transaction, the director now owns 7,555 shares of the company’s stock, valued at $812,540.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael C. Macdonald sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $90.74, for a total transaction of $453,700.00. Following the transaction, the director now directly owns 284,456 shares of the company’s stock, valued at approximately $25,811,537.44. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. grew its stake in Medifast by 31.4% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 45,150 shares of the specialty retailer’s stock valued at $5,758,000 after acquiring an additional 10,792 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Medifast by 5.9% in the 4th quarter. Rhumbline Advisers now owns 37,005 shares of the specialty retailer’s stock worth $4,055,000 after acquiring an additional 2,070 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Medifast by 1.8% in the 4th quarter. Swiss National Bank now owns 22,700 shares of the specialty retailer’s stock worth $2,487,000 after acquiring an additional 400 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Medifast by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 118,467 shares of the specialty retailer’s stock worth $12,982,000 after acquiring an additional 327 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of Medifast in the 4th quarter worth approximately $299,000.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.

Featured Story: What does a bar chart display?

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.